Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21
Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks with high potential. On October 3, Piper Sandler raised the firm’s price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) to $31 from $21 while keeping an Overweight rating on the shares.
The rating update came after the firm hosted Ocular Therapeutix Inc.’s (NASDAQ:OCUL) management at an investor dinner after its investor day, discussing aspects such as the newly disclosed diabetic retinopathy pivotal trial designs and the anticipated SOL-1 readout in Q1 2026.
The firm further stated that it raised its peak risk-adjusted sales estimates for AXPAXLI from $1.9 billion to $3.2 billion, based on the increased confidence in the wet AMD and NPDR Phase 3 programs.
Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical company that develops and commercializes therapies for conditions and diseases related to the eye. The company’s product pipeline includes Dextenza, OTX-TP, and OTX-TIC.
While we acknowledge the potential of OCUL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Content Original Link:
" target="_blank">
